Torrent Pharmaceuticals Ltd

Torrent Pharmaceuticals announced that Pranav Mehta, Executive Director (Strategic Planning) designated as Senior Management Personnel of the Company has tendered his resignation effective from close of business hours on 26 February 2025.Powered by Capital Market - Live

Torrent Pharmaceuticals Ltd gained for a third straight session today. The stock is quoting at Rs 3265.2, up 3.29% on the day as on 12:49 IST on the NSE. The benchmark NIFTY is down around 0.11% on the day, quoting at 23577.4. The Sensex is at 77848.44, down 0.27%. Torrent Pharmaceuticals Ltd has slipped around 1.79% in last one month. Meanwhile, Nifty Pharma index of which Torrent Pharmaceuticals Ltd is a constituent, has slipped around 4.1% in last one month and is currently quoting at 22009.05, up 0.26% on the day. The volume in the stock stood at 3.71 lakh shares today, compared to the daily average of 3.67 lakh shares in last one month. The benchmark February futures contract for the stock is quoting at Rs 3269.3, up 2.89% on the day. Torrent Pharmaceuticals Ltd is up 23.41% in last one year as compared to a 8.56% spurt in NIFTY and a 19.15% spurt in the Nifty Pharma index.The PE of the stock is 58.65 based on TTM earnings ending December 24.Powered by Capital Market - Live

Torrent Pharmaceuticals Ltd is down for a fifth straight session today. The stock is quoting at Rs 3104.75, down 2.02% on the day as on 13:19 IST on the NSE. The benchmark NIFTY is up around 1.17% on the day, quoting at 23634.9. The Sensex is at 78168.76, up 1.27%.Torrent Pharmaceuticals Ltd has eased around 7.68% in last one month.Meanwhile, Nifty Pharma index of which Torrent Pharmaceuticals Ltd is a constituent, has eased around 5.88% in last one month and is currently quoting at 21361.6, up 1.66% on the day. The volume in the stock stood at 4.65 lakh shares today, compared to the daily average of 2.9 lakh shares in last one month. The benchmark February futures contract for the stock is quoting at Rs 3118.35, down 2.15% on the day. Torrent Pharmaceuticals Ltd jumped 17.44% in last one year as compared to a 8.56% rally in NIFTY and a 18.72% spurt in the Nifty Pharma index.The PE of the stock is 58.78 based on TTM earnings ending December 24.Powered by Capital Market - Live

Revenue from operations grew 2.6% year on year (YoY) to Rs 2,762 crore in the quarter ended 31 December 2024. Profit before tax stood at Rs 691 crore in December 2024 quarter, up 9.5% from Rs 631 crore posted in same quarter last year. Operating EBITDA stood at Rs 914 crore in Q3 FY25, registering a growth of 5% as against Rs 869 crore reported in Q3 FY24. The operating EBITDA margin improved to 32.5%, up from 31.8% in the previous year. The company's revenue in India grew by 12% to Rs 1,581 crore in Q3 FY25, led by outperformance in focus therapies. As per AIOCD secondary market data, IPM growth for the quarter was 8%. Torrent's chronic business grew at 14% vs IPM growth of 10% On a MAT basis Torrent has outperformed the market across focused therapies aided by strong new launch performance. Torrent has 20 brands in the Top 500 brands in IPM, with 13 brands more than 100 crore. Torrent Pharma's revenue from Brazil decreased by 7% to Rs 291 crore, impacted by the steep depreciation of the BRL. In constant currency terms, revenue stood at R$ 203 million, reflecting a 10% increase. According to IQVIA QTD Nov 24, Torrent's growth was 14%, compared to the market growth of 12%. The growth was driven by the performance of top brands and recent new launches. Revenue from Germany stood at Rs 282 crore, an increase of 4%. In constant currency terms, revenue was '31 million, also up by 4%. The growth momentum continues, driven by incremental tender wins and better conversion of existing tenders. The company's US revenue stood at Rs 271 crore, down by 1%. In constant currency terms, revenue was $32 million, down by 3% compared to the same period in the previous year. During the quarter, the USFDA issued an EIR with a VAI classification for the manufacturing facility at Pithampur, Madhya Pradesh, and the inspection has now been successfully closed by the USFDA. As of 31 December 2024, 26 ANDAs were pending approval with the USFDA, and 6 tentative approvals had been received. During the quarter, 2 ANDAs were approved. Meanwhile, the company has announced an interim dividend of Rs 26 per equity share. The dividend is expected to be paid or dispatched on or around 17 February 2025. Additionally, the company has informed that Dr. Maurice Chagnaud will complete his term as an independent director on 10 May 2025. Torrent Pharmaceuticals is the flagship company of the Torrent Group. It is ranked 7th in the Indian Pharmaceuticals Market and is among the Top 5 in the therapeutic segments of Cardiovascular (CV), Gastrointestinal (GI), Central Nervous System (CNS), and Cosmo-Dermatology. Powered by Capital Market - Live

Torrent Pharmaceuticals announced that interim dividend of Rs 26 per equity share of Rs 5 fully paid up will be paid on or around 17 February 2025. Powered by Capital Market - Live

Net profit of Torrent Pharmaceuticals rose 13.54% to Rs 503.00 crore in the quarter ended December 2024 as against Rs 443.00 crore during the previous quarter ended December 2023. Sales rose 2.64% to Rs 2762.00 crore in the quarter ended December 2024 as against Rs 2691.00 crore during the previous quarter ended December 2023. ParticularsQuarter EndedDec. 2024Dec. 2023% Var. Sales2762.002691.00 3 OPM %33.0932.29 - PBDT890.00756.00 18 PBT691.00543.00 27 NP503.00443.00 14 Powered by Capital Market - Live

Torrent Pharmaceuticals announced that the Board of Directors of the Company at its meeting held on 24 January 2025, inter alia, have recommended the interim dividend of Rs 26 per equity Share (i.e. 520%) , subject to the approval of the shareholders.Powered by Capital Market - Live

Torrent Pharmaceuticals will hold a meeting of the Board of Directors of the Company on 24 January 2025.Powered by Capital Market - Live

Torrent Pharmaceuticals Ltd is up for a fifth straight session in a row. The stock is quoting at Rs 3464, up 2.43% on the day as on 12:44 IST on the NSE. The benchmark NIFTY is down around 0.98% on the day, quoting at 23962.25. The Sensex is at 79274.83, down 1.13%. Torrent Pharmaceuticals Ltd has risen around 11.67% in last one month. Meanwhile, Nifty Pharma index of which Torrent Pharmaceuticals Ltd is a constituent, has risen around 3.99% in last one month and is currently quoting at 22314.55, up 1.32% on the day. The volume in the stock stood at 3.15 lakh shares today, compared to the daily average of 3.56 lakh shares in last one month. The benchmark December futures contract for the stock is quoting at Rs 3468.45, up 2.22% on the day. Torrent Pharmaceuticals Ltd is up 61.34% in last one year as compared to a 13.3% spurt in NIFTY and a 40.24% spurt in the Nifty Pharma index.The PE of the stock is 69.93 based on TTM earnings ending September 24.Powered by Capital Market - Live

The brands include Cospiaq (empagliflozin), Cospiaq Met (empagliflozin + metformin) and Xilingio (empagliflozin + linagliptin), which are used in the treatment of type 2 diabetes. Empagliflozin is a novel sodium glucose co-transporter-2 (SGLT-2) inhibitor which is indicated for glycemic control in adults with type 2 diabetes mellitus. The market for SGLT-2 inhibitors is valued at Rs 3,235 crore and the SGLT-2 inhibitors are growing faster than the diabetes market at 25% CAGR. As per the International Diabetes Federation, India has the second largest diabetes patient base in the world with an estimated 74.2 million adults (20-79 years age group) as of 2021. This is expected to increase to almost 125 million patients by 2045. According to AWACS MAT October 2024 data, the Indian diabetes medications market is valued at Rs 19,912 crore, growing at 7.7% CAGR over the last 4 years. The acquisition is expected to be completed in March 2025. The company has been marketing these brands since 2022 as part of an existing co-marketing agreement with Boehringer Ingelheim India. Torrent Pharmaceuticals is the flagship company of the Torrent Group. It is ranked 6th in the Indian Pharmaceuticals Market and is amongst the top five in the therapeutics segments of cardiovascular (CV), gastro intestinal (GI), central nervous system (CNS), vitamins minerals nutritional (VMN) and cosmo-dermatology. The company's consolidated net profit increased 17.35% to Rs 453 crore on 8.6% rise in revenue from operations to Rs 2,889 crore in Q2 FY25 over Q2 FY24. The scrip shed 0.31% to Rs 3,339.25 on the BSE. Powered by Capital Market - Live